Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Book Volume: 9

Article Number: 103464

Journal Issue: 6

DOI: 10.1016/j.esmoop.2024.103464

Abstract

Background: Based on the findings of the PACIFIC trial, consolidation durvalumab following platinum-based chemoradiotherapy (CRT) is a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). An earlier analysis from the ongoing PACIFIC-R study (NCT03798535) demonstrated the effectiveness of this regimen in terms of progression-free survival (PFS). Here, we report the first planned overall survival (OS) analysis. Patients and methods: PACIFIC-R is an observational/non-interventional, retrospective study of patients with unresectable, stage III NSCLC who started durvalumab (10 mg/kg intravenously every 2 weeks) within an AstraZeneca-initiated early access program between September 2017 and December 2018. Primary endpoints are OS and investigator-assessed PFS, estimated using the Kaplan–Meier method. Results: By 30 November 2021, the full analysis set included 1154 participants from 10 countries (median follow-up in censored patients: 38.7 months). Median OS was not reached, and the 3-year OS rate was 63.2% (95% confidence interval 60.3% to 65.9%). Three-year OS rates were numerically higher among patients with programmed death-ligand 1 (PD-L1) expression on ≥1% versus <1% of tumor cells (TCs; 67.0% versus 54.4%) and patients who received concurrent CRT (cCRT) versus sequential CRT (sCRT) (64.8% versus 57.9%). Conclusions: PACIFIC-R data continue to provide evidence for the effectiveness of consolidation durvalumab after CRT in a large, diverse, real-world population. Better outcomes were observed among patients with PD-L1 TCs ≥1% and patients who received cCRT. Nevertheless, encouraging outcomes were still observed among patients with TCs <1% and patients who received sCRT, supporting use of consolidation durvalumab in a broad population of patients with unresectable, stage III NSCLC.

Authors with CRIS profile

Involved external institutions

The University of Liverpool United Kingdom (GB) Policlinico San Matteo Pavia Fondazione IRCCS Italy (IT) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) Hôpital Intercommunal de Créteil (CHIC) France (FR) Kliniken Essen-Mitte Germany (DE) University of Chicago United States (USA) (US) Universidad de Alcalá (UAH) Spain (ES) Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet Norway (NO) Chris O’Brien Lifehouse Australia (AU) Cabrini Health Australia (AU) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) Hospices Civils de Lyon (CHU) France (FR) Rambam Health Care Campus Israel (IL) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV) Switzerland (CH) Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Peter MacCallum Cancer Centre Australia (AU) Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC) Netherlands (NL) Onze-Lieve-Vrouwziekenhuis (OLV Ziekenhuis, OLVZ) Belgium (BE) University of Cambridge United Kingdom (GB) Institut Curie France (FR)

How to cite

APA:

Filippi, A.R., Bar, J., Chouaid, C., Christoph, D.C., Field, J.K., Fietkau, R.,... Girard, N. (2024). Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open, 9(6). https://doi.org/10.1016/j.esmoop.2024.103464

MLA:

Filippi, A. R., et al. "Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R." ESMO Open 9.6 (2024).

BibTeX: Download